Theromics is pioneering advanced thermal accelerant technologies through its proprietary nanopolymer platform, specifically the HeatSYNC™ and CryoSYNC gels. These biocompatible gels are designed to enhance thermal ablation procedures by improving energy transfer within human tissue, which addresses common challenges such as inaccurate targeting and heat loss due to blood flow. The gels facilitate larger and more effective ablation zones, potentially reducing the recurrence rate of soft tissue ablation treatments, which currently stands at around 30%. By optimizing the shape and size of the ablation area, Theromics aims to improve the precision of tumor targeting and overall treatment efficacy.

In addition to their application in thermal ablation, Theromics' nanogels are also being developed for targeted drug delivery, particularly in combination with existing therapies. This innovative approach, termed Thermally Activated Combination Therapy (TACT), allows for the direct injection of the gel into diseased tissue, enabling a controlled release of therapeutics while minimizing systemic side effects. The versatility of the HeatSYNC™ gel makes it compatible with various energy sources and ablation modalities, positioning it as a promising solution for conditions such as uterine fibroids and potentially other applications in women's health and cancer treatment.

United States

Theromics has developed a novel, safe Thermal Accelerant used during the microwave, RFA, or cryoablation procedures of soft tissue, fibroids, and bone HeatSYNC can augment the reach of thermal energy from a distance normally unattainable by microwave or radiofrequency devices, thus high-power energy is not needed. The gel is also being studied for use as a drug delivery system combined with thermal ablation for a new therapy called TACT - Thermally Activated Combination Therapy.

Theromics

Company Details